Switching from Rivaroxaban to Warfarin: Pharmacodynamics, Safety Assessed in Study

Heart Failure and LUTS: Managing Competing Drugs
Heart Failure and LUTS: Managing Competing Drugs
Because of various clinical situations, there may be a need for clinicians to transition patients from one anticoagulant therapy to another. In order to do this safely, the pharmacology profiles of both agents should be taken into consideration.

The primary objective was to explore the pharmacodynamic changes during transition from rivaroxaban to warfarin in healthy subjects. Safety, tolerability and pharmacokinetics were assessed as secondary objectives.

  • Latest News Your top articles for Thursday

  • Haymarket Medical NetworkTop Picks

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More